Literature DB >> 8043326

Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

D de Bono1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8043326      PMCID： PMC1025439          DOI： 10.1136/hrt.71.6.504

Source DB:  PubMed          Journal:  Br Heart J        ISSN： 0007-0769


× No keyword cloud information.
  40 in total

1.  Synthesis of a fibrinolytic activator and inhibitor by endothelial cells.

Authors:  D J Loskutoff; T E Edgington
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

2.  Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.

Authors:  J Auwerx; R Bouillon; D Collen; J Geboers
Journal:  Arteriosclerosis       Date:  1988 Jan-Feb

3.  Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women.

Authors:  I M Nilsson; P Felding; I Lecander; C Lennér; B Astedt
Journal:  Br J Haematol       Date:  1986-02       Impact factor: 6.998

4.  Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture.

Authors:  I Juhan-Vague; M C Alessi; C Fossat; P J Declerck; E K Kruithof
Journal:  Thromb Haemost       Date:  1987-12-18       Impact factor: 5.249

5.  Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.

Authors:  J Mehta; P Mehta; D Lawson; T Saldeen
Journal:  J Am Coll Cardiol       Date:  1987-02       Impact factor: 24.094

6.  Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).

Authors:  C Kluft; A F Jie; D C Rijken; J H Verheijen
Journal:  Thromb Haemost       Date:  1988-04-08       Impact factor: 5.249

7.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

8.  Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery.

Authors:  A W Clowes; M M Clowes; T R Kirkman; C L Jackson; Y P Au; R Kenagy
Journal:  Circ Res       Date:  1992-06       Impact factor: 17.367

9.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

Authors:  A Hamsten; B Wiman; U de Faire; M Blombäck
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

10.  Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.

Authors:  R R Schleef; M P Bevilacqua; M Sawdey; M A Gimbrone; D J Loskutoff
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157
View more
  15 in total

1.  Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers?

Authors:  Antonio Tello-Montoliu; Vanessa Roldán; Vicente E Climent; Francisco Sogorb; Gregory Y H Lip; Francisco Marín
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

2.  Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo.

Authors:  D E Newby; F N Witherow; R A Wright; P Bloomfield; C A Ludlam; N A Boon; K A A Fox; D J Webb
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

3.  Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation.

Authors:  S R Kahn; S Solymoss; K M Flegel
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

4.  Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction.

Authors:  Robin A P Weir; Sean Balmain; Tracey Steedman; Leong L Ng; Iain B Squire; Anne Rumley; Henry J Dargie; Gordon D O Lowe
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

5.  Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.

Authors:  G H Tofler; J Massaro; C J O'Donnell; P W F Wilson; R S Vasan; P A Sutherland; J B Meigs; D Levy; R B D'Agostino
Journal:  Thromb Res       Date:  2016-02-03       Impact factor: 3.944

6.  Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension.

Authors:  Salvatore Paterna; Vincenzo Di Garbo; Gino Avellone; Pietro Di Pasquale; Antonina Cacia; Antonio Tuttolomondo; Giuseppe Follone; Antonietta Cardinale; Tiziana Maniscalchi; Giuseppe Licata
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

7.  Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetic men with and without coronary heart disease.

Authors:  S G Wannamethee; G D O Lowe; A G Shaper; A Rumley; L Lennon; P H Whincup
Journal:  Diabetologia       Date:  2004-09-09       Impact factor: 10.122

8.  Influence of stearic acid on hemostatic risk factors in humans.

Authors:  Tine Tholstrup
Journal:  Lipids       Date:  2005-12       Impact factor: 1.880

9.  The Role of Hemostatic Factors in Atherosclerosis in Patients with Chronic Renal Disease.

Authors:  Manal Zahran; Fatma Mohammed Nasr; Amna Ahmed Metwaly; Noha El-Sheikh; Nevine Sherif Ali Khalil; Tarek Harba
Journal:  Electron Physician       Date:  2015-09-16

10.  Acute coronary syndromes: from the laboratory markers to the coronary vessels.

Authors:  Palazzuoli Alberto; Iovine Francesca; Scali Chiara; Nuti Ranuccio
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.